Table 2.
Prevalence of autoantibodies in 863 scleroderma patients
| Autoantibodies | Patients, n (%) |
|---|---|
| Positive for antinuclear antibodies | 813 (94.2) |
| Antibodies highly associated with SSc or scleroderma overlap syndromes | 704 (81.6) |
| Anti-centromere | 310 (35.9) |
| Anti-topoisomerase I | 260 (30.1) |
| Anti-PM-Scl | 42 (4.9) |
| Anti-U1-RNP | 41 (4.8) |
| Anti-RNA polymerase | 33 (3.8) |
| Anti-fibrillarin | 12 (1.4) |
| Anti-To | 2 (0.2) |
| Anti-Ku | 10 (1.2) |
| Anti-Jo-1/-Pl-7/-OJ | 4 (0.5) |
| Anti-U11-RNP | 1 (0.1) |
| Other autoantibodies | |
| Anti-Ro and/or anti-La | 206 (23.9) |
| Anti-Ro52 | 187 (21.7) |
| Anti-Ro60 | 59 (6.8) |
| Anti-La | 16 (1.9) |
| Anti-mitochondrial M2 | 41 (4.8) |
| Anti-p25/p23 | 28 (3.2) |
| Anti-NOR-90 | 6 (0.7) |
| Anti-SL | 9 (1.0) |
| Anti-Sm | 4 (0.5) |
| Anti-Sp100 | 4 (0.5) |
| Other (known or unknown) | 363 (42.1) |
| Negative for all highly SSc-associated antibodies | 159 (18.4) |
| Negative for antinuclear antibodies | 50 (5.8) |
| Autoantibody-negative by all criteria used | 38 (4.4) |
ANA = antinuclear antibodies; SSc = systemic sclerosis.